|
|
Volumn 9, Issue 3, 2010, Pages 235-237
|
|
Tarenflurbil for Alzheimer's disease: a "shot on goal" that missed
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
AMYLOID BETA PROTEIN;
BIOLOGICAL MARKER;
CHOLINESTERASE INHIBITOR;
FLUORODEOXYGLUCOSE;
GAMMA SECRETASE;
HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;
MEMANTINE;
PLACEBO;
TARENFLURBIL;
ALZHEIMER DISEASE;
CEREBROSPINAL FLUID;
CLINICAL ASSESSMENT;
CLINICAL TRIAL;
COGNITION;
CORONARY ARTERY DISEASE;
DAILY LIFE ACTIVITY;
DISEASE COURSE;
DRUG EFFICACY;
DRUG WITHDRAWAL;
ENZYME INHIBITION;
HEART FAILURE;
HUMAN;
LETTER;
NEUROIMAGING;
NUCLEAR MAGNETIC RESONANCE IMAGING;
OUTCOME ASSESSMENT;
POSITRON EMISSION TOMOGRAPHY;
PRIORITY JOURNAL;
RATING SCALE;
ALZHEIMER DISEASE;
ANIMALS;
CLINICAL TRIALS, PHASE III AS TOPIC;
FLURBIPROFEN;
GOALS;
HUMANS;
|
|
EID: 76449092591
PISSN: 14744422
EISSN: None
Source Type: Journal
DOI: 10.1016/S1474-4422(10)70030-2 Document Type: Letter |
|
Times cited : (18)
|
|
References (4)
|
